Morgan Stanley Vor Biopharma Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Vor Biopharma Inc. stock. As of the latest transaction made, Morgan Stanley holds 126,692 shares of VOR stock, worth $115,289. This represents 0.0% of its overall portfolio holdings.

Number of Shares

126,692

Previous 172,061 26.37%

Holding current value

$115,289

Previous $387,000 22.48%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.8 - $2.85 $81,664 - $129,301	-45,369 Reduced 26.37%	126,692 $300,000
Q4 2023 Feb 13, 2024	BUY	$1.66 - $2.63 $157,761 - $249,947	95,037 Added 123.39%	172,061 $387,000
Q3 2023 Nov 15, 2023	BUY	$2.1 - $3.35 $64,684 - $103,186	30,802 Added 66.64%	77,024 $163,000
Q2 2023 Aug 14, 2023	SELL	$3.09 - $5.33 $71,851 - $123,938	-23,253 Reduced 33.47%	46,222 $142,000
Q1 2023 May 15, 2023	BUY	$4.68 - $6.96 $245,798 - $365,546	52,521 Added 309.79%	69,475 $373,000

Q4 2022 Feb 14, 2023	BUY	$3.98 - $7.43 $36,942 - $68,965	9,282 Added 120.99%	16,954 $112,000
Q3 2022 Nov 14, 2022	SELL	$4.36 - $5.52 $98,527 - $124,740	-22,598 Reduced 74.65%	7,672 $30,000
Q2 2022 Oct 27, 2022	BUY	$3.89 - $6.44 $78,356 - $129,720	20,143 Added 198.9%	30,270 $150,000
Q2 2022 Aug 15, 2022	BUY	$3.89 - $6.44 $78,356 - $129,720	20,143 Added 198.9%	30,270 $150,000
Q1 2022 Oct 27, 2022	SELL	$6.04 - $12.23 $121,663 - $246,348	-20,143 Reduced 66.54%	10,127 $60,000
Q1 2022 May 13, 2022	BUY	$6.04 - $12.23 $5,387 - $10,909	892 Added 9.66%	10,127 $60,000
Q4 2021 Feb 14, 2022	SELL	$11.32 - $18.02 $479,730 - $763,669	-42,379 Reduced 82.11%	9,235 $108,000
Q3 2021 Nov 15, 2021	BUY	$12.24 - $20.38 $631,755 - $1.05 Million	51,614 New	51,614 $809,000

Others Institutions Holding VOR

# of Institutions

Shares Held

29M

Call Options Held

1.8K

Put Options Held

100

View Full List

About Vor Biopharma Inc.

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $34.6M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

More about VOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account